Inactive Instrument

Evogene Ltd. TEL AVIV STOCK EXCHANGE

Equities

EVGN

IL0011050551

Biotechnology & Medical Research

Evogene Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021

March 10, 2022 at 07:00 am EST

Evogene Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 0.93 million compared to USD 1.04 million a year ago. Net loss was USD 27.79 million compared to USD 23.37 million a year ago.

Basic loss per share from continuing operations was USD 0.69 compared to USD 0.83 a year ago.

Latest news about Evogene Ltd.

Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd	Apr. 02	CI
Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq	Mar. 20	MT
Transcript : Evogene Ltd., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Evogene Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Evogene Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Evogene Unit, Corteva Agriscience Identify New Potential Class of Herbicidal Molecules	Mar. 06	MT
AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides	Mar. 06	CI
Casterra Announces New Agreements with Subsidiary of Evogen Ltd., to Meet Growing Demand for Its Elite Castor Seed Varieties	Mar. 05	CI
Evogene Files $200 Million Mixed Shelf	Mar. 01	MT
Evogene Ltd. and Verb Biotics LLC Enters into Collaboration Agreement	Feb. 06	CI
Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024	Dec. 19	CI
Transcript : Evogene Ltd., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Earnings Flash (EVGN) EVOGENE Posts Q3 Revenue $3.8M	Nov. 15	MT
Evogene Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Colors Farm Ltd, Evogene Ltd. and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology	23-10-31	CI
Alliance Global Starts Evogene at Buy With $1.85 Price Target	23-10-02	MT
Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	23-08-18	MT
Transcript : Evogene Ltd., Q2 2023 Earnings Call, Aug 17, 2023	23-08-17
Earnings Flash (EVGN) EVOGENE Posts Q2 Revenue $654,000	23-08-17	MT
Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery	23-07-25	CI
Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program	23-07-19	CI
Evogene Expects to Raise $8.5 Million in Gross Proceeds From Registered Direct Offering; Shares Fall	23-07-17	MT
Evogene's Lavie Bio Says Corteva to Develop, Commercialize Lead Fungicide Product Candidates	23-07-17	MT
Evogene Subsidiary Receives Additional $2.2 Million in Purchase Orders for Castor Seeds	23-07-03	MT

Chart Evogene Ltd.

Duration

Period

More charts

Company Profile

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.62%	42.59B
MODERNA, INC.	+7.83%	40.65B
LONZA GROUP AG	+48.54%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.29%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.17B
MEDPACE HOLDINGS, INC.	+28.65%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.93%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.36%	11.1B

Other Biotechnology & Medical Research